ClinicalTrials.gov
ClinicalTrials.gov Menu

Observation Study of the Medication Switch at Patients Treated With Sitaxentan to a Regime Without Sitaxentan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01281371
Recruitment Status : Completed
First Posted : January 21, 2011
Last Update Posted : June 27, 2013
Sponsor:
Information provided by:
Heidelberg University

Brief Summary:
Due to the withdrawal of Thelin (Sitaxentan) in December 2010 all patients with pulmonary hypertension treated with Sitaxentan need to be switched to an alternative therapy. This study will observe in which way the change of medication - in the clinical routine, without exception in charge of the treating physician - affects clinical and laboratory parameters and patient's quality of life.

Condition or disease
Hypertension, Pulmonary

Study Type : Observational
Actual Enrollment : 9 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Devolution of a Medication Change at Patients With Mono- or Combination Therapy With Sitaxentan to a Regime Without Sitaxentan.
Study Start Date : January 2011
Actual Primary Completion Date : June 2013
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine





Biospecimen Retention:   Samples With DNA
only remaining blood of the security laboratory for analysis of plasma concentrations of drugs


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients treated with Sitaxentan
Criteria

Inclusion Criteria:

  • Pulmonary hypertension
  • Treatment with Sitaxentan

Exclusion Criteria:

  • Inability or unwillingness to give written informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01281371


Locations
Germany
Department of Clinical Pharmacology and Pharmacoepidemiology, Medical department of the University of Heidelberg
Heidelberg, Baden-Württemberg, Germany, 69120
Sponsors and Collaborators
Heidelberg University
Investigators
Principal Investigator: Walter E. Haefeli, Prof. Dr. med. Department of Clinical Pharmacology and Pharmacoepidemiology

Responsible Party: Prof. Dr. med. Walter E. Haefeli, Department of Clinical Pharmacology and Pharmacoepidemiology
ClinicalTrials.gov Identifier: NCT01281371     History of Changes
Other Study ID Numbers: K344
First Posted: January 21, 2011    Key Record Dates
Last Update Posted: June 27, 2013
Last Verified: December 2010

Additional relevant MeSH terms:
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Sitaxsentan
Endothelin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action